Clinical trials: COVID
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique
A population-based COVID19 surveillance in a household cohort will be set-up using an existing Household demographic surveillance system (HDSS).
- Trial name
- AfriCoVER (NCT04442165)
- Where
- Mozambique
- Volunteers
- 6,049 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
COVID-19, Lung Injury, Acute
SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
This study will evaluate the safety of a 96-hour intravenous vitamin C infusion protocol (50 mg/kg every 6 hours) in patients with hypoxemia and suspected COVID-19.
- Conditions
- COVID-19, Lung Injury, Acute, Kidney Injury
- Trial name
- NCT04344184
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Virginia Commonwealth University
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
COVID-19
A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV-2 receptor binding domain (RBD) to COVID-19 patients.
- Trial name
- NCT04494984
- Testing
- INM005
- Where
- 19 sites in Argentina
- Volunteers
- 243 people
- Sponsor
- Inmunova S.A.
Post COVID-19 Condition, Long COVID
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
- Trial name
- NCT05592418
- Testing
- Rintatolimod
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- AIM ImmunoTech Inc.
Infectious Disease, Cancer
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
People with cancer may be at higher risk of poor outcomes with COVID-19 infection. This observational study aims to describe the clinical course of COVID-19 infection in people with cancer and evaluate the utility of antibody and…
- Conditions
- Infectious Disease, Cancer, Coronavirus Infection
- Trial name
- CARDS (NCT04427280)
- Testing
- Throat/nose swabs, Saliva collection, Blood collection
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Royal Marsden NHS Foundation Trust
SARS-CoV-2, COVID-19
Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04403880
- Testing
- Sample collection
- Where
- 53 sites in United States, Malawi and 4 more
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
SARS-CoV-2
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two potential treatments for hospitalized patients with confirmed SARS-CoV-2…
- Trial name
- NCT04335552
- Testing
- Standard of care, Hydroxychloroquine, Azithromycin
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
SARS-CoV-2
Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities
Repeat testing for SARS-CoV-2 antibodies in disadvantaged communities will help identify active and recovered infections over time, and as more is understood about antibody protection, it may help identify persons who have…
- Trial name
- NCT04901624
- Testing
- Family Risk Messaging, Personal Risk Messaging, Loss Protection
- Where
- United States
- Volunteers
- 2,164 people
- Sponsor
- University of Southern California
Diabetes Mellitus, Type 2, Covid19
Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
The COVID-19 pandemic has triggered extremely high hospitalization rates where mitigation strategies are urgently necessary to aid vulnerable Hispanic and Latino populations who are experiencing health disparities as well as high…
- Trial name
- NCT04591015
- Testing
- Hospital: DD-CA, Hospital: Usual Care (UC)
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Scripps Whittier Diabetes Institute
Covid19
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved…
- Trial name
- NCT04969250
- Testing
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Where
- 30 sites in United States, Nigeria and 4 more
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Upper Respiratory Tract Infections, Virus
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected…
- Conditions
- Upper Respiratory Tract Infections, Virus, COVID, Virus Shedding
- Trial name
- NCT04382131
- Testing
- NaCl Solution
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Edinburgh
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
COVID-19 Disease, SARS Pneumonia
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
This prospective, single-center, randomized, placebo-controlled, observer-blind Phase 1/2 study includes two separate parts. Part 1 is a first-in-human, Phase 1 study designed to evaluate the safety, tolerability and…
- Conditions
- COVID-19 Disease, SARS Pneumonia, Pneumonia, Viral, COVID-19 Vaccine
- Trial name
- NCT04830800
- Testing
- COVIVAC, Phosphate-buffered saline
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Corona Virus Infection, SARS-CoV 2
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial…
- Conditions
- Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
- Trial name
- NCT04374565
- Testing
- High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Virginia
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline